Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
30
04
2022
received:
24
07
2021
accepted:
21
05
2022
pubmed:
25
5
2022
medline:
9
9
2022
entrez:
24
5
2022
Statut:
ppublish
Résumé
The coexistence of pachyonychia congenita (PC) and hidradenitis suppurativa (HS) has been described in case reports. However, the pathomechanism underlying this association and its true prevalence are unknown. To determine the genetic defect underlying the coexistence of PC and HS in a large kindred, to delineate a pathophysiological signalling defect jointly leading to both phenotypes, and to estimate the prevalence of HS in PC. We used direct sequencing and a NOTCH luciferase reporter assay to characterize the pathophysiological basis of the familial coexistence of HS and PC. A questionnaire was distributed to patients with PC registered with the International Pachyonychia Congenita Research Registry (IPCRR) to assess the prevalence of HS among patients with PC. Direct sequencing of DNA samples obtained from family members displaying both PC and HS demonstrated a missense variant (c.275A>G) in KRT17, encoding keratin 17. Abnormal NOTCH signalling has been suggested to contribute to HS pathogenesis. Accordingly, the KRT17 c.275A>G variant resulted in a significant decrease in NOTCH activity. To ascertain the clinical importance of the association of HS with PC, we distributed a questionnaire to all patients with PC registered with the IPCRR. Seventy-two of 278 responders reported HS-associated clinical features (25·9%). Disease-causing mutations in KRT17 were most prevalent among patients with a dual phenotype of PC and HS (43%). The coexistence of HS and KRT17-associated PC is more common than previously thought. Impaired NOTCH signalling as a result of KRT17 mutations may predispose patients with PC to HS. What is already known about this topic? The coexistence of pachyonychia congenita (PC) and hidradenitis suppurativa (HS) has been described in case reports. However, the pathomechanism underlying this association and its true prevalence are unknown. What does this study add? A dual phenotype consisting of PC and HS was found to be associated with a pathogenic variant in KRT17. This variant was found to affect NOTCH signalling, which has been previously implicated in HS pathogenesis. HS was found to be associated with PC in a large cohort of patients with PC, especially in patients carrying KRT17 variants, suggesting that KRT17 variants causing PC may also predispose to HS. What is the translational message? These findings suggest that patients with PC have a higher prevalence of HS than previously thought, and hence physicians should have a higher level of suspicion of HS diagnosis in patients with PC.
Sections du résumé
BACKGROUND
The coexistence of pachyonychia congenita (PC) and hidradenitis suppurativa (HS) has been described in case reports. However, the pathomechanism underlying this association and its true prevalence are unknown.
OBJECTIVES
To determine the genetic defect underlying the coexistence of PC and HS in a large kindred, to delineate a pathophysiological signalling defect jointly leading to both phenotypes, and to estimate the prevalence of HS in PC.
METHODS
We used direct sequencing and a NOTCH luciferase reporter assay to characterize the pathophysiological basis of the familial coexistence of HS and PC. A questionnaire was distributed to patients with PC registered with the International Pachyonychia Congenita Research Registry (IPCRR) to assess the prevalence of HS among patients with PC.
RESULTS
Direct sequencing of DNA samples obtained from family members displaying both PC and HS demonstrated a missense variant (c.275A>G) in KRT17, encoding keratin 17. Abnormal NOTCH signalling has been suggested to contribute to HS pathogenesis. Accordingly, the KRT17 c.275A>G variant resulted in a significant decrease in NOTCH activity. To ascertain the clinical importance of the association of HS with PC, we distributed a questionnaire to all patients with PC registered with the IPCRR. Seventy-two of 278 responders reported HS-associated clinical features (25·9%). Disease-causing mutations in KRT17 were most prevalent among patients with a dual phenotype of PC and HS (43%).
CONCLUSIONS
The coexistence of HS and KRT17-associated PC is more common than previously thought. Impaired NOTCH signalling as a result of KRT17 mutations may predispose patients with PC to HS. What is already known about this topic? The coexistence of pachyonychia congenita (PC) and hidradenitis suppurativa (HS) has been described in case reports. However, the pathomechanism underlying this association and its true prevalence are unknown. What does this study add? A dual phenotype consisting of PC and HS was found to be associated with a pathogenic variant in KRT17. This variant was found to affect NOTCH signalling, which has been previously implicated in HS pathogenesis. HS was found to be associated with PC in a large cohort of patients with PC, especially in patients carrying KRT17 variants, suggesting that KRT17 variants causing PC may also predispose to HS. What is the translational message? These findings suggest that patients with PC have a higher prevalence of HS than previously thought, and hence physicians should have a higher level of suspicion of HS diagnosis in patients with PC.
Identifiants
pubmed: 35606927
doi: 10.1111/bjd.21674
pmc: PMC9796395
doi:
Substances chimiques
Keratin-17
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
392-400Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Références
J Invest Dermatol. 2011 Jul;131(7):1568-70
pubmed: 21412258
Br J Dermatol. 1998 Sep;139(3):475-80
pubmed: 9767294
Acta Derm Venereol. 2009 Nov;89(6):601-3
pubmed: 19997690
Br J Dermatol. 2011 Jun;164(6):1292-8
pubmed: 21332464
J Pathol. 2019 Feb;247(2):158-165
pubmed: 30306595
Hum Mol Genet. 1998 Jul;7(7):1143-8
pubmed: 9618173
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:42-44
pubmed: 31535759
Differentiation. 1987;35(3):236-48
pubmed: 2451629
Br J Dermatol. 2003 Mar;148(3):452-5
pubmed: 12653736
J Invest Dermatol. 2012 Oct;132(10):2459-2461
pubmed: 22622421
J Investig Dermatol Symp Proc. 2005 Oct;10(1):21-30
pubmed: 16250206
Nature. 2006 May 18;441(7091):362-5
pubmed: 16710422
J Invest Dermatol. 1997 Feb;108(2):220-3
pubmed: 9008238
Br J Dermatol. 2014 Dec;171(6):1565-7
pubmed: 24842198
J Am Acad Dermatol. 2012 Oct;67(4):680-6
pubmed: 22264670
J Invest Dermatol. 2011 Dec;131(12):2401-8
pubmed: 21796151
Br J Dermatol. 2020 Mar;182(3):738-746
pubmed: 31823354
An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):51-53
pubmed: 28300893
Br J Dermatol. 2011 Mar;164(3):610-6
pubmed: 21073448
J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:36-39
pubmed: 31535756
J Cell Sci. 1989 Jul;93 ( Pt 3):419-26
pubmed: 2481679
J Invest Dermatol. 2010 Feb;130(2):425-9
pubmed: 19609311
J Invest Dermatol. 2018 Aug;138(8):1736-1743
pubmed: 29758285
Exp Dermatol. 2013 Mar;22(3):172-7
pubmed: 23489419
J Am Acad Dermatol. 2019 Jul;81(1):76-90
pubmed: 30872156
Am J Pathol. 1993 Dec;143(6):1667-78
pubmed: 7504888
Br J Dermatol. 1996 Feb;134(2):247-56
pubmed: 8746337
Curr Opin Cell Biol. 2008 Apr;20(2):171-9
pubmed: 18342499
Nat Genet. 1995 Jul;10(3):363-5
pubmed: 7545493
Oncogene. 2016 Oct 27;35(43):5653-5662
pubmed: 27065324
J Am Acad Dermatol. 2020 May;82(5):1045-1058
pubmed: 31604104
Arch Dermatol. 1976 Aug;112(8):1132-4
pubmed: 988984
Br J Dermatol. 1990 Nov;123(5):663-6
pubmed: 2248894
Exp Dermatol. 2011 Mar;20(3):217-28
pubmed: 21323743
Clin Exp Dermatol. 2021 Jul;46(5):867-873
pubmed: 33486795
Oncol Rep. 2020 Jul;44(1):103-114
pubmed: 32627037
J Invest Dermatol. 2000 Jun;114(6):1101-7
pubmed: 10844551
J Clin Invest. 2010 Jan;120(1):103-14
pubmed: 20038814
J Invest Dermatol. 2011 May;131(5):1015-7
pubmed: 21430705
Exp Dermatol. 2000 Jun;9(3):170-7
pubmed: 10839714
Clin Exp Dermatol. 2010 Jun;35(4):e151-2
pubmed: 19886955
Br J Dermatol. 2013 Apr;168(4):876-8
pubmed: 23020871
Exp Dermatol. 2020 Dec;29(12):1154-1170
pubmed: 33058306
J Cell Sci. 2020 Oct 30;133(20):
pubmed: 33008845
Science. 2010 Nov 19;330(6007):1065
pubmed: 20929727